1Alonso-ValleH, Acha O, Garcia-Palomo J D, et al. Candidemia in a tertiary care hospital:epidmiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis,2003,22(4) :254.
4Reichenberger F, Habicht JM, Gratwohl A, et al. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J,2002,19 (4) :743 - 755.
5Takemoto K, Yamamoto Y, Ueda Y, et al. Comparative studies on the efficacy of amBisome and fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother, 2004,53 ( 2 ) : 311 - 317.
6Glasmacher Ao Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies : evidence from a meta - analysis of 3597 patients. J Clin Onco,2003,21 (24) :4615 -4626.
7Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive Pulmonary aspergillosis. Acta Haematol,2003,109 (3) : 111 - 118.
8Walsh TJ, Papps P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med,2002,346(4) : 225 - 234.
9PfaUer MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaeonazole, ravueonazole, and vorieonazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp and other filamentous fungi : report from SENTRY Antimicrobial Surveillance Program, 2000, Antimicrob Agents Chemother,2002,46(4) :1032 - 1037.
10Herbrecht R, Denning DW , Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med,2002,347(6) :408 -415.
2Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709.
3Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14.
4Denning DW,Kibbler CC,Barnes RA,et al.British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.Lancet Infect Dis,2003,3:230-240.
5Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis.Clin Infect Dis,2004,38:161-189.
6Slavin MA,Szer J,Grigg AP,et al.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Intern Med J,2004,34:192-200.
7Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clin Infect Dis,2000,30:710-718.
